Search Result

Results for "

Neuropsychiatric

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (9) Acetyl-CoA synthetase (1) Acyltransferase (1) Adenosine Receptor (1) Adrenergic Receptor (4) Arrestin (1) Biochemical Assay Reagents (1) Cannabinoid Receptor (1) Carbonic Anhydrase (1) Casein Kinase (1) Cholinesterase (ChE) (1) COX (1) Dopamine Receptor (12) Dopamine Transporter (1) Drug Derivative (2) Drug Isomer (3) Drug Metabolite (1) GABA Receptor (4) GPR52 (2) GSK-3 (1) HDAC (1) Histamine Receptor (4) iGluR (5) Isotope-Labeled Compounds (2) mAChR (5) mGluR (1) Monoamine Transporter (2) nAChR (7) Opioid Receptor (4) P-glycoprotein (1) PERK (1) Phosphodiesterase (PDE) (4) Phospholipase (1) PKA (1) Reference Standards (4) REV-ERB (1) Sigma Receptor (1) Somatostatin Receptor (1) Trace Amine-associated Receptor (TAAR) (3)
By Research Areas:	Cancer (4) Cardiovascular Disease (4) Endocrinology (3) Infection (2) Inflammation/Immunology (6) Metabolic Disease (4) Neurological Disease (72)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1395

Mecamylamine hydrochloride 5 Publications Verification	nAChR Histamine Receptor	Cardiovascular Disease Neurological Disease
Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine hydrochloride is also a ganglionic blocker. Mecamylamine hydrochloride can across the blood-brain barrier. Mecamylamine hydrochloride can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .

HY-148104

ACSS2-IN-2 1 Publications Verification	Acetyl-CoA synthetase	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
ACSS2-IN-2 is an acyl-CoA synthetase short-chain family member 2 (ACSS2) inhibitor. ACSS2-IN-2 can inhibit ACSS2 activity with an IC₅₀ value of 3.8 nM. ACSS2-IN-2 can be used for the research of several diseases, such as viral infection, metabolic disorders, neuropsychiatric diseases, inflammatory/autoimmune conditions and cancer .

HY-117516

SR10067	REV-ERB	Neurological Disease Metabolic Disease
SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC₅₀ values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders .

HY-103213

JP1302 dihydrochloride 2 Publications Verification	Adrenergic Receptor	Neurological Disease Endocrinology
JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α_2C-adrenoceptor, with a K_b of 16 nM and a K_i of 28 nM for the human α_2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research .

HY-109112

Brilaroxazine RP5063	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-159829

Direclidine NBI-1117568; HTL-0016878	mAChR	Neurological Disease
Direclidine (NBI-1117568, HTL-0016878) is a selective orthosteric agonist targeting the muscarinic acetylcholine M4 receptor, exhibiting very low affinity for M1, M2, M3, and M5 receptors. It binds to the orthosteric site of the M4 receptor in a non-covalent, competitive manner. Direclidine specifically activates the M4 receptor, inhibiting the release of acetylcholine from striatal cholinergic interneurons, thereby regulating the balance of the dopaminergic system and reducing psychiatric symptoms associated with excessive dopamine release. Direclidine can improve symptoms associated with neuropsychiatric disorders and is used in research on schizophrenia and other neuropsychiatric disorders .

HY-19348

Pimelic Diphenylamide 106 5 Publications Verification RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII	HDAC Monoamine Transporter	Neurological Disease Cancer
Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC₅₀ values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD) .

HY-157521

AANAT-IN-1	Acyltransferase	Neurological Disease Metabolic Disease
AANAT-IN-1 is an arylalkylamine N-acetyltransferase (AANAT) inhibitor with a sheep AANAT IC₅₀ of 9.9 μM. AANAT-IN-1 binds to the active site of sheep AANAT, interacting with amino acid residues via hydrogen bonds, hydrophobic interactions, ionic interactions, and water bridges, inhibiting the enzyme's catalytic activity. AANAT-IN-1 can be used for the researches of circadian rhythm-associated neuropsychiatric conditions, seasonal affective disorder, and other diseases associated with abnormally elevated melatonin levels .

HY-125751

UCSF924 1 Publications Verification	Dopamine Receptor	Neurological Disease
UCSF924, a chemical probe, is a potent and specific dopamine D4 receptor (DRD4) partial agonist with a EC₅₀ of 4.2 nM. UCSF924 has no off-target effects on more than 320 non-olfactory GPCRs. UCSF924 can be used for research in the field of neuropsychiatric diseases .

HY-103493

TAK-915	Phosphodiesterase (PDE)	Neurological Disease
TAK-915 is a potent, selective, brain-penetrant and orally active phosphodiesterase 2A (PDE2A) inhibitor with an IC₅₀ of 0.61 nM. TAK-915 is >4100-fold more selectivity for PDE2A than PDE1A. TAK-915 has the potential for neuropsychiatric and neurodegenerative disorders treatment .

HY-14826

Tilivapram AVE8112	Phosphodiesterase (PDE)	Neurological Disease
Tilivapram (AVE8112) is an orally active PDE4 inhibitor with procognitive effects. Tilivapram exhibits in vivo efficacy and improves processing speed and psychomotor speed. Oral administration of tilivapram may induce dose-related adverse reactions such as nausea and dizziness, but transdermal delivery enables slow, controlled elevation of plasma concentrations, thereby significantly reducing gastrointestinal discomfort and dizziness. Tilivapram is applicable to research related to neuropsychiatric disorders .

HY-176900

GPR52 agonist-4	GPR52	Neurological Disease
GPR52 agonist-4 (Compound 65) is a highly selective G-protein-coupled receptor GPR52 modulator. GPR52 agonist-4 is promising for research of neuropsychiatric diseases .

HY-116483

MPX-007	iGluR	Neurological Disease
MPX-007 is a GluN2A antagonist (IC₅₀: 27 nM). MPX-007 is a tools to probe GluN2A physiology, and to study neuropsychiatric and developmental disorders .

HY-103213A

JP1302 2 Publications Verification	Adrenergic Receptor	Neurological Disease
JP1302 is a potent, selective, high affinity antagonist of the α_2C-adrenoceptor, with a K_b of 16 nM and a K_i of 28 nM for the human α_2C-receptor. JP1302 shows antidepressant and antipsychotic-like effects. JP1302 can be used for neuropsychiatric disorders and renal dysfunction research .

HY-148939

MPX-004	iGluR	Neurological Disease
MPX-004 is a potent GluN2A antagonist. MPX-004 inhibits GluN2A-containing NMDA receptors expressed in HEK cells with an IC₅₀ of 79 nM. MPX-004 has no inhibitory effect on GluN2B or GluN2D receptor-mediated responses. MPX-004 has the potential for neuropsychiatric and developmental disorders research .

HY-163671

PW0729	GPR52	Neurological Disease
PW0729 (compound 15b) is an orphan GPR52 agonist with potential applications in GPR52 activation, signaling bias, and neuropsychiatric and neurological disorders. The brain exposure characteristics of PW0729 need to be further optimized .

HY-103054

RO5203648	Trace Amine-associated Receptor (TAAR)	Neurological Disease
RO5203648 is a potent and highly selective partial agonist of TAAR1 (Trace amine-associated receptor 1) with high affinity. RO5203648 demonstrates a novel paradigm for neuropsychiatric research .

HY-14840A

(R)-Phenylpiracetam MRZ 9547	Dopamine Transporter	Neurological Disease Inflammation/Immunology
(R)-Phenylpiracetam (MRZ 9547) is a dopamine transporter (DAT) inhibitor (K_i: 14.8 μM; IC₅₀: 65.5 μM). (R)-Phenylpiracetam can be used for the research of the neurological or neuropsychiatric disorders .

HY-172995

RS130-180	5-HT Receptor	Neurological Disease
RS130-180 is a selective β-arrestin-biased agonist targeting the serotonin 2A receptor (5-HT_2aR). RS130-180 is promising for research of neuropsychiatric disorders such as depression .

HY-179291

5-HT2A agonist 8	5-HT Receptor	Neurological Disease
5-HT2A agonist 8 (Compound 67) is a 5-HT_2A agonist, with an EC₅₀ of 4 nM. 5-HT2A agonist 8 can be used in the research of neuropsychiatric and neurodegenerative diseases .

HY-B1395A

Mecamylamine	nAChR Histamine Receptor	Cardiovascular Disease Neurological Disease
Mecamylamine is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine is also a ganglionic blocker. Mecamylamine can across the blood-brain barrier. Mecamylamine can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .

HY-P1386

D15 Dynamin II (828–842)	iGluR	Neurological Disease
D15, a peptide with 15 aa segment of dynamin, is an AMPAR endocytosis inhibitor. D15 blocks the interaction of dynamin with amphiphysin 1 and 2. D15 significantly increases AMPAR excitatory postsynaptic potential (EPSC) amplitude of medium spiny neurons (MSNs) in Sapap3 KO mice. D15 can be used for neuropsychiatric disorder research .

HY-176287

ARN25657	Dopamine Receptor GSK-3 PKA P-glycoprotein	Neurological Disease
ARN25657 is a dual-acting D3R/GSK-3β modulator. ARN25657 has both partial D3R agonist activity (EC₅₀ = 15.2 nM, K_i=1.5 nM) and potent GSK-3β inhibitor activity (IC₅₀ = 19.3 nM). ARN25657 exhibits excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. ARN25657 inhibits P-glycoprotein (P-gP)-mediated acetoxymethyl calcein efflux and improves in vitro ADME properties while maintaining a balanced dual-target profile. ARN25657 is useful for studying bipolar disorder and related neuropsychiatric disorders .

HY-N12125

Entadamide A	Others	Infection
Entadamide A (compound 1) is a tryptophan derivative. Entadamide A prevents tryptophan depletion by inhibiting indoleamine 2, 3-dioxygenase (IDO), thereby inhibiting HIV replication. Entadamide A can be used in drug and neuropsychiatric studies of redesivir [1].

HY-175504

MLS6357	Dopamine Receptor PERK	Neurological Disease
MLS6357 is a D3 dopamine receptor (D3R)-selective positive allosteric modulator (PAM)-antagonist. MLS6357 exhibits antagonist activity in the D3R-mediated and the BRET-based β-arrestin recruitment assay with IC₅₀s of 13 and 14 μM, and no activity for other DAR subtypes (D1R/D2R/D4R/D5R) (IC₅₀ > 100 μM). MLS6357 is also an antagonist in the D3R-mediated Go-BRET assay with an IC₅₀ of 17 μM. MLS6357 can be used for the study of neuropsychiatric disorders, including substance use disorder .

HY-116430

(S)-SKF-77434 (S)-APB	Dopamine Receptor Drug Isomer	Neurological Disease
(S)-SKF-77434 (Compound 11) ((S)-APB) is an enantiomer of SKF-77434 (HY-103417). (S)-SKF-77434 shows an affinity for the D₁ receptor with an IC₅₀ of 2800 nM. (S)-SKF-77434 can be used in the research of neuropsychiatric disorders .

HY-172981

CTW0404	5-HT Receptor	Neurological Disease
CTW0404 is a potent 5-HT Receptor positive allosteric modulators (PAMs). CTW0404 is promising for research of neuropsychiatric disorders .

HY-172982

CTW0419	5-HT Receptor	Neurological Disease
CTW0419 is a potent 5-HT Receptor positive allosteric modulators (PAMs). CTW0419 is promising for research of neuropsychiatric disorders .

HY-P5756

CSD-CH2(1,8)-NH2	Opioid Receptor	Neurological Disease
CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (K_i: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .

HY-19130

BW-534U87	Adenosine Receptor	Neurological Disease
BW-534U87 is an orally active adenosine A1 receptor agonist and competitive adenosine deaminase (ADA) inhibitor (K_i=7 μM). BW-534U87 elevates brain adenosine levels and suppresses epileptiform activity. BW-534U87 demonstrate anticonvulsant efficacy in animal seizure models. BW-534U87 is promising for research of epilepsy and adenosine-related neuropsychiatric disorders .

HY-400648

Folic acid methyl ester	Drug Metabolite	Cancer
Folic acid methyl ester is a methyl ester metabolite of folic acid that can be used in the study of neuropsychiatric conditions, such as depression ^{[1] ^.}

HY-128856

P7C3-OMe	Drug Derivative	Neurological Disease
P7C3-OMe is a pro-neurogenic compound, has therapeutic benefits in neuropsychiatric and/or neurodegenerative disease. The R-enantiomer of P7C3-OMe is far more active than the S-enantiomer .

HY-103522

AA29504	GABA Receptor	Neurological Disease
AA29504 is a ethyl carbamate with γ-aminobutyric acid (GABAA(HY-L120) receptor activity. AA29504 inhibits the delivery of the neurotransmitter gamma-aminobutyric acid in the central nervous system. AA29504 can be used to research anxiety, insomnia and other neuropsychiatric diseases .

HY-169951

Lu AF90103	iGluR	Neurological Disease
Lu AF90103 (Compound 42e) is a methyl ester prodrug of compound 42d capable of penetrating the blood-brain barrier. Compound 42d acts as a partial agonist of the GluN1/GluN2B complex, exhibiting 24% efficacy, and has an EC₅₀ value of 78 nM. Lu AF90103 plays an important role in neuropsychiatric diseases research .

HY-15977

(S)-P7C3-OMe	Drug Isomer	Neurological Disease
(S)-P7C3-OMe, P7C3-A20 hydroxylated analog, is the (S)-enantiomer of P7C3-OMe. P7C3-OMe is a pro-neurogenic compound, can be used for the research of neuropsychiatric and/or neurodegenerative disease .

HY-106949

Tazomeline	mAChR	Neurological Disease
Tazomeline is a selective M1 muscarinic receptor agonist. Tazomeline inhibits twitch height in rabbit vas deferens(IC₅₀= 0.001 nM). Tazomeline can be used for research of neuropsychiatric disorders .

HY-149481

D4R agonist-1	Dopamine Receptor	Neurological Disease
D4R agonist-1 (Compound 16f) is a D4R partial agonist (K_i: 2.2 nM). D4R agonist-1 is metabolically stable in rat and human liver microsomes. D4R agonist-1 can be used for research of neuropsychiatric disorders .

HY-176505

NOP antagonist 1	Opioid Receptor	Neurological Disease
NOP antagonist 1 (Compound (-)-31) is a nociceptin opioid peptide (NOP) antagonist with a K_b of 8.65  nM. NOP antagonist 1 can be used for neuropsychiatric disorders research .

HY-174152

GABAB receptor antagonist 5	GABA Receptor	Neurological Disease
GABAB receptor antagonist 5 (Compound 23) is a competitive GABA_B receptor antagonist. GABAB receptor antagonist 5 is promising for research of neuropsychiatric diseases, such as epilepsy, depression, and addiction .

HY-148224

Pifoxime	COX	Inflammation/Immunology
Pifoxime is a COX-1/2 inhibitor, a non-steroidal anti-inflammatory agent (NSAID). Pifoxime shows anti-inflammatory activity, and can be used in neuropsychiatric research .

HY-155319

μ opioid receptor agonist 3	Opioid Receptor	Neurological Disease
μ opioid receptor agonist 3 (compound 20) is a potent μ opioid receptor (µOR) agonist with an EC₅₀ of 0.87 nM. μ opioid receptor agonist 3 has the potential for pain and neuropsychiatric indications research .

HY-W909149

TAAR1 agonist 3	Trace Amine-associated Receptor (TAAR) Adrenergic Receptor	Neurological Disease
TAAR1 agonist 3 is a trace amine-associated receptor 1 (TAAR1) agonist (pEC₅₀=7.6). TAAR1 agonist 3 is also a full agonist of the α_2A receptor (pEC₅₀=6). TAAR1 agonist 3 can be used in the study of neuropsychiatric diseases .

HY-136258

nAChR agonist CMPI hydrochloride	nAChR	Neurological Disease
nAChR agonist CMPI hydrochloride is a potent and selective positive allosteric modulator (PAM) of nAChR containing a α4:α4 subunit interface. nAChR agonist CMPI hydrochloride enhances the response of (α4)₃(β2)₂ nAChR to ACh (10 µM) with an EC₅₀ of 0.26 µM. nAChR agonist CMPI hydrochloride has potential for the research of nicotine dependence and many neuropsychiatric conditions associated with decreased brain cholinergic activity .

HY-171981

VU6002703	mAChR	Neurological Disease
VU6002703 (Compound 17) is a BBB-penetrable M4 mAChR positive allosteric modulator (PAM) with an EC₅₀ of 0.6  μM for hM4. VU6002703 can be used for neuropsychiatric and rare genetic CNS disorders research .

HY-169038

11(Z),14(Z)-Eicosadienoic acid ethanolamide	Cannabinoid Receptor Drug Derivative	Neurological Disease
11(Z),14(Z)-Eicosadienoic acid ethanolamide (Compound 3) is an ethanolamide-conjugated form of 11(Z),14(Z)-Eicosadienoic acid (HY-149589). 11(Z),14(Z)-Eicosadienoic acid ethanolamide inhibits the inactivating transport of an endogenous cannabinoid substance with an IC₅₀ value of 10.6 μM. 11(Z),14(Z)-Eicosadienoic acid ethanolamide can be used for research of neuropsychiatric conditions .

HY-169163

BChE-IN-36	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease
hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with K_A values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC₅₀ values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .

HY-W909173

TAAR1 agonist 2	Trace Amine-associated Receptor (TAAR) Histamine Receptor mAChR	Neurological Disease
TAAR1 agonist 2 (compound 30) is a full agonist of trace amine-associated receptor 1 (TAAR1) (pEC₅₀=7.5). TAAR1 agonist 2 also exhibits agonist activity at H1 receptors and activates several members of the muscarinic acetylcholine receptor family, such as the M2 receptor (pEC₅₀=5). TAAR1 agonist 2 can be used in the study of neuropsychiatric diseases .

HY-177278

SST1 receptor antagonist-1	Somatostatin Receptor	Neurological Disease Endocrinology Cancer
SST1 receptor antagonist-1 (Compound 23) is a selective Somatostatin receptor 1 (SST1) antagonist with pK_ds of 9.11 and 8.79 for rSST1 and hSST1, respectively. SST1 receptor antagonist-1 can be used for retinal and endocrine dysfunctions, cancer and neuropsychiatric disorders research .

HY-B1395R

Mecamylamine hydrochloride (Standard)	Reference Standards nAChR Histamine Receptor	Cardiovascular Disease Neurological Disease
Mecamylamine (hydrochloride) (Standard) is the analytical standard of Mecamylamine (hydrochloride). This product is intended for research and analytical applications. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist. Mecamylamine hydrochloride is also a ganglionic blocker. Mecamylamine hydrochloride can across the blood-brain barrier. Mecamylamine hydrochloride can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area .

HY-103213R

JP1302 dihydrochloride (Standard)	Reference Standards Adrenergic Receptor	Neurological Disease Endocrinology
JP1302 dihydrochloride (Standard) is the analytical standard of JP1302 dihydrochloride. This product is intended for research and analytical applications. JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α2C-adrenoceptor, with a Kb of 16 nM and a Ki of 28 nM for the human α2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research .

Cat. No.	Product Name

HY-L120

GABA Receptor Compound Library

209 compounds

GABA receptors are a class of receptors that respond to the neurotransmitter gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter in the vertebrate central nervous system. There are two classes of GABA receptors: GABAA and GABAB. GABAA receptors are ligand-gated ion channels (also known as ionotropic receptors), whereas GABAB receptors are G protein-coupled receptors (also known asmetabotropic receptors). GABA receptors are significant drug targets in the treatment of neuropsychiatric disorders such as epilepsy, insomnia, and anxiety, as well as in anesthesia in surgical operations.

MCE offers a unique collection of 209 GABA receptors inhibitors and activators, which is an efficient tool for neuropsychiatric disorders drugs discovery.

HY-L121

5-HT Receptor Compound Library

405 compounds

5-HT receptors, also called Serotonin receptors, are a group of G protein-coupled receptors (GPCRs) and ligand-gated ion channels (LGICs) found in the central and peripheral nervous systems. These receptors are now classified into seven families, 5-HT1–7, comprising a total of 14 structurally and pharmacologically distinct mammalian 5-HT receptor subtypes. The 5-HT receptors influence various biological and neurological processes such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, andthermoregulation. The serotonin receptors are the target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens.

MCE 5-HT Receptor Compound Library consists of 405 5-HT receptor inhibitors and activators, which can be used for neuropsychiatric disorders drugs discovery.

Cat. No.	Product Name	Target	Research Area

HY-P1386

D15 Dynamin II (828–842)	iGluR	Neurological Disease
D15, a peptide with 15 aa segment of dynamin, is an AMPAR endocytosis inhibitor. D15 blocks the interaction of dynamin with amphiphysin 1 and 2. D15 significantly increases AMPAR excitatory postsynaptic potential (EPSC) amplitude of medium spiny neurons (MSNs) in Sapap3 KO mice. D15 can be used for neuropsychiatric disorder research .

HY-P5756

CSD-CH2(1,8)-NH2	Opioid Receptor	Neurological Disease
CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (K_i: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12125

Entadamide A	Natural Products Petasites formosanus Kitam. Leguminosae Plants Source Classification	Others
Entadamide A (compound 1) is a tryptophan derivative. Entadamide A prevents tryptophan depletion by inhibiting indoleamine 2, 3-dioxygenase (IDO), thereby inhibiting HIV replication. Entadamide A can be used in drug and neuropsychiatric studies of redesivir [1].

Cat. No.	Product Name	Chemical Structure

HY-B1395S

Mecamylamine-d3 hydrochloride
Mecamylamine-d₃ hydrochloride is the deuterium labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders. Mecamylamine hydrochloride is originally used as a ganglionic blocker in treating hypertension. Mecamylamine hydrochloride can easily crosses the blood-brain barrier .

HY-B1395S1

Mecamylamine hydrochloride-13C4,15N

Mecamylamine (hydrochloride)- ¹³C₄, ¹⁵N is the ¹³C-labeled and ¹⁵N-labeled Mecamylamine hydrochloride. Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR antagonist that can treat various neuropsychiatric disorders. Mecamylamine hydrochloride is originally used as a ganglionic blocker in treating hypertension. Mecamylamine hydrochloride can easily crosses the blood-brain barrier .

Cat. No.	Product Name		Classification